69 related articles for article (PubMed ID: 3548961)
1. Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study.
Carlson RW; Billingham ME; Kohler M; Johnson FD; Doroshow JH; Torti FM
Cancer Treat Rep; 1987 Apr; 71(4):427-8. PubMed ID: 3548961
[No Abstract] [Full Text] [Related]
2. Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group.
Carlson RW; Williams RD; Billingham ME; Kohler M; Torti FM
Cancer Treat Rep; 1987; 71(7-8):767-8. PubMed ID: 3607787
[No Abstract] [Full Text] [Related]
3. Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
Locker GY; Hoeltgen T; Kilton L; Krauss S; McNamara M; Blough R; Johnson C
Cancer Treat Rep; 1987; 71(7-8):765-6. PubMed ID: 3300969
[No Abstract] [Full Text] [Related]
4. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
Fiore J; Kemeny N; Raymond V; Young C
Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
[No Abstract] [Full Text] [Related]
5. Phase II trial of 4'-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study.
Meyers FJ; Lewis B; Mitchell E; William L; Hannigan JF; Gribble M; Torti FM
Cancer Treat Rep; 1985 Jan; 69(1):143-4. PubMed ID: 3855385
[No Abstract] [Full Text] [Related]
6. An oriented phase II trial of THP-adriamycin in breast carcinoma.
Mathé G; Umezawa H; Oka S; Misset JL; Brienza S; de Vassal F; Musset M; Ribaud P; Tapiero H
Biomed Pharmacother; 1986; 40(10):376-9. PubMed ID: 3580506
[TBL] [Abstract][Full Text] [Related]
7. Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma.
Smith IE; Coombes RC; Evans BD; Ford HT; Gazet JC; Gordon C; McKinna JA; Powles TJ
Eur J Cancer (1965); 1980; Suppl 1():271-3. PubMed ID: 7032939
[No Abstract] [Full Text] [Related]
8. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
DiStefano A; Yap HY; Blumenschein GR
Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of THP (2''R)-4'-0-tetrahydropyranyladriamycin) in breast cancer].
Abe O; Enomoto K; Tominaga T; Kasai Y; Soejima S; Kasai M; Izuo M; Yoshida M; Kubo K; Terasawa T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):578-85. PubMed ID: 3954379
[TBL] [Abstract][Full Text] [Related]
12. Polychemotherapeutic treatment of patients with metastatic breast cancer.
Balázs M; Tüske M
Acta Med Hung; 1986; 43(4):407-11. PubMed ID: 3601586
[TBL] [Abstract][Full Text] [Related]
13. [New 2004 guidelines of the Breast Organ Committee of AGO].
Krankenpfl J; 2004; 42(3-4):81. PubMed ID: 15311888
[No Abstract] [Full Text] [Related]
14. Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer.
Borovik R; Epelbaum R; Cohen Y; Robinson E
Cancer Treat Rep; 1986 Apr; 70(4):517-8. PubMed ID: 3698045
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
16. Relationship between estrogen-receptor proteins and response to chemotherapy in breast cancer.
Levine RM; Lippman ME
Cancer Treat Rep; 1984 Apr; 68(4):573-6. PubMed ID: 6370427
[No Abstract] [Full Text] [Related]
17. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Ibrahim NK; Frye DK; Buzdar AU; Walters RS; Hortobagyi GN
Arch Intern Med; 1996 Apr; 156(8):882-8. PubMed ID: 8774207
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of breast cancer. Investigational treatment.
Jones SE
Ariz Med; 1974 Mar; 31(3):197-8. PubMed ID: 4362033
[No Abstract] [Full Text] [Related]
20. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Stearns V; Singh B; Tsangaris T; Crawford JG; Novielli A; Ellis MJ; Isaacs C; Pennanen M; Tibery C; Farhad A; Slack R; Hayes DF
Clin Cancer Res; 2003 Jan; 9(1):124-33. PubMed ID: 12538460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
